hema.to offers a cloud‑based machine learning platform that automates and personalises the clinical analysis of blood data (cytometry) to bring precision diagnostics to immune medicine. The company built a world‑first AI prototype in collaboration with Europe’s largest leukemia lab and found that many labs share the same manual workflows and pain points. Founded two years ago by three former entrepreneurs (with three PhD profiles) who are ex res mechanica, hema.to aims to help labs across the world and scale its solution across European laboratories. The startup has raised a €3.6 million seed round to finance growth. Proceeds will be used to grow its team of software engineers and immunologists/cytometrists and to scale its AI capabilities. The product focus is clinical cytometry workflow automation and AI‑assisted analysis; no revenue or user metrics were disclosed in the article.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2023